Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.
Anna S DeanMatteo ZignolAndrea Maurizio CabibbeDennis FalzonPhilippe GlaziouDaniela Maria CirilloClaudio U KöserLice Y Gonzalez-AnguloOlga Tosas-AugetNazir IsmailSabira TahseenMaria Cecilia G AmaAlena SkrahinaNatavan AlikhanovaS M Mostofa KamalKatherine FloydPublished in: PLoS medicine (2020)
In this study, the prevalence of Hr-TB among TB patients was higher than the prevalence of rifampicin resistance globally. Many patients with Hr-TB would be missed by current diagnostic algorithms driven by rifampicin testing, highlighting the need for new rapid molecular technologies to ensure access to appropriate treatment and care. The low prevalence of resistance to pyrazinamide and fluoroquinolones among patients with Hr-TB provides further justification for the recommended modified treatment regimen.
Keyphrases
- mycobacterium tuberculosis
- end stage renal disease
- risk factors
- newly diagnosed
- cross sectional
- ejection fraction
- chronic kidney disease
- pulmonary tuberculosis
- prognostic factors
- machine learning
- emergency department
- electronic health record
- patient reported outcomes
- hepatitis c virus
- combination therapy
- genome wide
- chronic pain
- health insurance
- big data
- gene expression
- copy number
- adverse drug
- patient reported
- drug induced
- antiretroviral therapy